EGFR and non-small cell lung carcinoma: In contrast, the multicenter, prospective phase 3 clinical trials CheckMate 722 and KEYNOTE-789, which aimed to validate the efficacy of ICI plus chemotherapy in patients with NSCLC who presented with EGFR mutation, showed a trend of prolonged PFS.